within Pharmacolibrary.Drugs.ATC.A;

model A16AX22
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 8.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX22</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tiomolibdic acid, also known as bis-choline tetrathiomolybdate, is a chelating agent mainly investigated for the treatment of Wilson's disease, a rare genetic disorder of copper metabolism. It acts by binding copper and preventing its toxic accumulation. It is not approved in all countries for clinical use but has received orphan drug designation and has been approved in the EU under the name Cufence.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic studies reporting specific parameters for tiomolibdic acid (bis-choline tetrathiomolybdate) in humans were identified. The following parameters are estimated based on typical values for chelating agents administered orally.</p><h4>References</h4><ol><li><p>Buzalaf, MAR, et al., &amp; Ten Cate, JM (2011). Mechanisms of action of fluoride for caries control. <i>Monographs in oral science</i> 22 97–114. DOI:<a href=&quot;https://doi.org/10.1159/000325151&quot;>10.1159/000325151</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21701194/&quot;>https://pubmed.ncbi.nlm.nih.gov/21701194</a></p></li><li><p>Peng, B, et al., &amp; Schran, H (2005). Clinical pharmacokinetics of imatinib. <i>Clinical pharmacokinetics</i> 44(9) 879–894. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544090-00001&quot;>10.2165/00003088-200544090-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16122278/&quot;>https://pubmed.ncbi.nlm.nih.gov/16122278</a></p></li><li><p>Jinhua, W (2019). Ursolic acid: Pharmacokinetics process in vitro and in vivo, a mini review. <i>Archiv der Pharmazie</i> 352(3) e1800222–None. DOI:<a href=&quot;https://doi.org/10.1002/ardp.201800222&quot;>10.1002/ardp.201800222</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30663087/&quot;>https://pubmed.ncbi.nlm.nih.gov/30663087</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX22;
